Severe acute respiratory syndrome

Darling Ingredients Inc. Announces Closing of Private Offering of $750 Million of Unsecured Senior Notes due 2030

Retrieved on: 
Thursday, June 9, 2022
Public expenditure, United Kingdom, Collagen, Poultry, Company, Food, Securities Act of 1933, LinkedIn, Influenza A virus subtype H1N1, Legislation, Biofuel, Software, Meat, Security (finance), Meal, ASF, Bovine spongiform encephalopathy, Government, Failure, U.S. Securities and Exchange Commission, DAR, Regulation, Natural gas, Sale, Private Securities Litigation Reform Act, NYSE, COVID-19, Pandemic, Compliance, Grain, SARS, African swine fever virus, Union, Epidemic, Edible, Industry, Plant, BSE, Severe acute respiratory syndrome, SEC Rule 144A, PED, Bird Flu, Person, Disease, Cattle, Bank

IRVING, Texas, June 9, 2022 /PRNewswire/ -- Darling Ingredients Inc. (NYSE: DAR) ("Darling" or the "Company") today announced the closing of its private offering of $750 million aggregate principal amount of its unsecured senior notes due 2030 (the "notes").

Key Points: 
  • IRVING, Texas, June 9, 2022 /PRNewswire/ -- Darling Ingredients Inc. (NYSE: DAR) ("Darling" or the "Company") today announced the closing of its private offering of $750 million aggregate principal amount of its unsecured senior notes due 2030 (the "notes").
  • The notes bear interest at 6% per annum, payable semi-annually in arrears on June 15 and December 15 of each year, commencing on December 15, 2022.
  • Darling may temporarily apply proceeds to reduce revolving credit indebtedness or invest in cash equivalents, U.S. government securities and other high-quality debt investments pending application of the proceeds.
  • Darling Ingredients Inc. (NYSE: DAR) isthe largest publicly traded company turning edible by-products and food waste into sustainable products and a leading producer of renewable energy.

Darling Ingredients Inc. Announces Closing of Private Offering of $750 Million of Unsecured Senior Notes due 2030

Retrieved on: 
Thursday, June 9, 2022
Public expenditure, United Kingdom, Collagen, Poultry, Company, Food, Securities Act of 1933, LinkedIn, Influenza A virus subtype H1N1, Legislation, Biofuel, Software, Meat, Security (finance), Meal, ASF, Bovine spongiform encephalopathy, Government, Failure, U.S. Securities and Exchange Commission, DAR, Regulation, Natural gas, Sale, Private Securities Litigation Reform Act, NYSE, COVID-19, Pandemic, Compliance, Grain, SARS, African swine fever virus, Union, Epidemic, Edible, Industry, Plant, BSE, Severe acute respiratory syndrome, SEC Rule 144A, PED, Bird Flu, Person, Disease, Cattle, Bank

IRVING, Texas, June 9, 2022 /PRNewswire/ -- Darling Ingredients Inc. (NYSE: DAR) ("Darling" or the "Company") today announced the closing of its private offering of $750 million aggregate principal amount of its unsecured senior notes due 2030 (the "notes").

Key Points: 
  • IRVING, Texas, June 9, 2022 /PRNewswire/ -- Darling Ingredients Inc. (NYSE: DAR) ("Darling" or the "Company") today announced the closing of its private offering of $750 million aggregate principal amount of its unsecured senior notes due 2030 (the "notes").
  • The notes bear interest at 6% per annum, payable semi-annually in arrears on June 15 and December 15 of each year, commencing on December 15, 2022.
  • Darling may temporarily apply proceeds to reduce revolving credit indebtedness or invest in cash equivalents, U.S. government securities and other high-quality debt investments pending application of the proceeds.
  • Darling Ingredients Inc. (NYSE: DAR) isthe largest publicly traded company turning edible by-products and food waste into sustainable products and a leading producer of renewable energy.

Fresenius Kabi Introduces New Generic for the Treatment of Multiple Myeloma

Retrieved on: 
Monday, May 2, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Birth, Toxicity, Multiple myeloma, Lymphocytopenia, Dehydration, Mannitol, Female, Thrombocytopenia, CEO, Nausea, Risk, Bortezomib, MRI, Mantle cell lymphoma, Fresenius (company), Peripheral neuropathy, Patient, Thrombotic microangiopathy, Program, Heart, FDA, Incidence, Industry, Diabetes, Constipation, Vomiting, Anaphylaxis, Injection, Cardiotoxicity, Fatigue, Diarrhea, Mantle, Internet, Tumor lysis syndrome, Purging disorder, Multimedia, Fetus, Neuralgia, LLC, Blood, Degenerative disease, Boron, Leukopenia, Cancer, Hypersensitivity, Hypotension, Anemia, Rash, Severe acute respiratory syndrome, Adult, MD Anderson Cancer Center, Science, Pharmaceutical industry, Vaccine, Health insurance, Medical device, Medical imaging, Birth control, Online gambling, Neutropenia, Fever

Fresenius Kabi Bortezomib for Injection is an affordable treatment option for adult patients with multiple myeloma and mantle cell lymphoma .

Key Points: 
  • Fresenius Kabi Bortezomib for Injection is an affordable treatment option for adult patients with multiple myeloma and mantle cell lymphoma .
  • Were pleased to be able to provide an affordable option to patients and we are especially pleased that Fresenius Kabi Bortezomib for Injection is produced at one of our U.S. facilities.
  • To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
  • Fresenius Kabi ( www.fresenius-kabi.com/us ) is a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition.

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Epidemiology Research Report, 2019-2021 & 2022-2032 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 7, 2022
Infectious Diseases, Pharmaceutical, Health, Table, Diagnosis, United Kingdom, SARS, Epidemiology, Coronavirus, Disease, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, Classification, Animal, Pharmaceutical industry

This "Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Key Points: 
  • This "Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection epidemiology report gives a thorough understanding of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis.
  • The Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection epidemiology covered in the report provides historical as well as forecasted Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
  • The Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
    The Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Epidemiology Report and Model provide an overview of the global trends of Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
    The report provides insight into the historical and forecasted patient pool of Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan

The World Market for Veterinary Diagnostics 2021-2026: Featuring Key Players IDEXX, Thermo Fisher Scientific, Heska Corporation and Zoetis - ResearchAndMarkets.com

Retrieved on: 
Monday, March 7, 2022
Pets, Consumer, TGE, Betaarterivirus suid 1, Infection, Classical swine fever, Journal of Veterinary Diagnostic Investigation, Country, Magic: The Gathering core sets, 1993–2007, PRRS, Severe acute respiratory syndrome, Immunoassay, BVD, Molecular diagnostics, Row, Bovine viral diarrhea, Transmissible spongiform encephalopathy, Clinical chemistry, Companion, Vaccine, Medical device, Pet, Hematology, Growth, Food Animal Concerns Trust

The "The World Market for Veterinary Diagnostics, 5th Edition " report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The World Market for Veterinary Diagnostics, 5th Edition " report has been added to ResearchAndMarkets.com's offering.
  • The World Market for Veterinary Diagnostics, 5th Edition examines the worldwide veterinary diagnostics market through the performance of its two component markets of companion animal and food animal diagnostics.
  • The report provides an analysis of major veterinary disease markets as well as overall market performance and development.
  • Total Global Animal Diagnostic Testing Market, 2021-2026 (in millions $ at manufacturer level)
    Global Veterinary Diagnostic Testing Market Share by Region (%) 2021 (US, Europe, Asia Pacific, RoW)
    Food Animal Diagnostics Market by Infectious Disease (Bovine Viral Diarrhea [BVD], Classical Swine Fever [CSF], Enzootic Bovine Leukosis [EBL], Infectious Bovine Tracheitis [IBR], Porcine Coronavirus Diseases [PEDv, PDCoV, TGE], Porcine Reproductive and Respiratory Syndrome [PRRS], Pseudorabies/Aujeszky's, Transmissible Spongiform Encephalopathies [TSEs], Other) (% and $ millions) 2021
    The World Market for Veterinary Diagnostics, 5th Edition contains the following market data points for both the food animal and companion animal segments:
    Global Animal Diagnostic Testing Market by Animal Segment, 2021-2026 (in millions $ at manufacturer level)
    Veterinary Companion Diagnostics Market Segmentation 2021 (Companion Animal: Clinical Chemistry, Infectious disease, Hematology, Other Analyzers, Non-infect Immunodiagnostics, Molecular, Other Testing, Total; Food Animal: Immunodiagnostic Test Kits, Molecular Diagnostics, Clinical Chemistry, Other Infectious Disease Test Reagents, Total) ($million; %)
    Market Size and Growth for United States Diagnostic Testing Market, 2021-2026 ($millions)
    Market Size and Growth for European Diagnostics Testing Market, 2021-2026 ($millions)
    Market Size and Growth for Asia Pacific Diagnostic Testing Market, 2021-2026 ($millions)
    Asia Pacific Diagnostic Testing by Country Percent 2018 (Japan, Philippines, China, India, Others)
    Market Size and Growth for Rest of World Diagnostic Testing Market, 2021-2026 ($millions)
    RoW Companion Animal Diagnostic Testing by Country Percent 2021 (Companion Animal: Canada, Australia, Brazil, Mexico, Others; Food Animal: Canada, Brazil, Mexico, Others)

$1.99 Bn N95 Medical Protective Masks Markets - Global Industry Analysis 2015-2019 & Growth Trends and Market Forecasts 2020-2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 3, 2022
Medical Supplies, Health, Infection, Health care, Patient, Korea Disease Control and Prevention Agency, Mask, Ansell, Safety, Coronavirus, Severe acute respiratory syndrome, COVID-19, Time, Cardinal Health, CAGR, CM, Center, N95, Pet, Personal protective equipment

The "N95 Medical Protective Masks Market - Global Industry Analysis (2015 - 2019) - Growth Trends and Market Forecast (2020 - 2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "N95 Medical Protective Masks Market - Global Industry Analysis (2015 - 2019) - Growth Trends and Market Forecast (2020 - 2026)" report has been added to ResearchAndMarkets.com's offering.
  • The global N95 medical protective masks market will be worth US$1,994.8.0 Mn by 2026 from US$ 1,159.4.0 Mn in 2020.
  • During the forecast years of 2020 to 2026, the global market for N95 medical protective masks will register a CAGR of 9.5%.
  • The hospital and clinic segment will hold a 59% market share in the global N95 medical protective masks market.

Non-Invasive Ventilation Masks Industry to Cross $2.58 Billion by 2028 - Analysis and Projections by Product, Application, End-user, and Region - ResearchAndMarkets.com

Retrieved on: 
Monday, February 28, 2022
Medical Devices, Health, Failure rate, Mask, Pyaar Tune Kya Kiya (TV series), Pharmacy, Method, Growth, WHO, Prevalence, Center, Awareness, Anatomy, COVID-19, Industry, BioMed Central, World, Centers for Disease Control and Prevention timeline, Person, Severe acute respiratory syndrome, Euclidean distance, TB, ICU, Infection, NIV, Pressure, Geography, Death, Patient, World Health Organization, CAGR, Acute exacerbation of chronic obstructive pulmonary disease, Mortality, Time, SARS, Restaurant, Vaccine, Marketing, Tuberculosis, H1N1

The global non-invasive ventilation masks market is likely to reach the value of US$ 1,776.04 million in 2021 and is projected to reach US$ 2,583.06 million by 2028.

Key Points: 
  • The global non-invasive ventilation masks market is likely to reach the value of US$ 1,776.04 million in 2021 and is projected to reach US$ 2,583.06 million by 2028.
  • The prevalence of chronic obstructive pulmonary diseases, and infectious diseases is increasing worldwide, fueling the need for non-invasive ventilation masks substantially.
  • However, the side effects of NIV masks may limit the demand, hampering the market during the forecast period.
  • Based on the end-user, the non-invasive ventilation masks market is segmented into ICU, pediatric, home care, and others.

SARS Coronavirus Infection Industry Report 2022-2032: Insights, Trends, and Future State of Worldwide Markets - ResearchAndMarkets.com

Retrieved on: 
Friday, February 25, 2022
Infectious Diseases, Pharmaceutical, Health, Comprehension, Therapy, Gaps, Awareness, Severe acute respiratory syndrome coronavirus, Epidemiology, Clinical trial, PESTLE, Disease, SWOT, Table, Acquisition, Growth–share matrix, Severe acute respiratory syndrome, Competition, News, SME, Technology, Porter's five forces analysis, Research, Lists of people executed in the United States, SARS, Animal, Pharmaceutical industry, Coronavirus, Phase II

This report delivers an in-depth understanding of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, historical and forecasted epidemiology as well as the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Key Points: 
  • This report delivers an in-depth understanding of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, historical and forecasted epidemiology as well as the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection market report provides current treatment practices, emerging drugs, Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection market share of the individual therapies, current and forecasted Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection market size from 2019 to 2032 segmented by seven major markets.
  • The Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection epidemiology division provide insights about historical and current Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection patient pool and forecasted trend for every seven major countries.
  • Drug chapter segment of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection report encloses the detailed analysis of Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.

Brondell Releases Thinnest Luxury Bidet Toilet Seat on the Market

Retrieved on: 
Monday, January 3, 2022
Ecosystem, COVID-19, Science, Hygiene, Engineering, FDA, Plasma, Cornell University, Bacteria, Restaurant, SAN, Health, Fender Telecaster Thinline, Duke Diet and Fitness Center, Atmosphere, Drinking, School, Life, Food, Severe acute respiratory syndrome, Hong Kong Science and Technology Parks Corporation, Smoke, Vaccine, Research, SARS, Virus, Food and Drug Administration, Organic compound, Volatile organic compound, University, Jean-Baptiste Brondel, Technology, Tissue paper, Nanocrystalline material, Omicron, Delta

SAN FRANCISCO, Jan. 3, 2022 /PRNewswire/ -- Brondell, a pioneer in innovation focusing on health and personal care technologies in North America, announces the release of the Swash Thinline Electronic Luxury Bidet Toilet Seat.

Key Points: 
  • SAN FRANCISCO, Jan. 3, 2022 /PRNewswire/ -- Brondell, a pioneer in innovation focusing on health and personal care technologies in North America, announces the release of the Swash Thinline Electronic Luxury Bidet Toilet Seat.
  • At under 4 inches in height, it is the thinnest bidet toilet seat on the market today.
  • While all bidet toilet seats offer a hygienic, eco-friendly alternative to toilet paper, many are overly large and bulky, maintaining the outdated look and feel of an old-fashioned medical device.
  • Brondell is the only company to maintain the right to sell and market its own air purifier using AG+ Technology in North America.

Roche receives CE mark for the use of saliva samples with cobas SARS-CoV-2 Qualitative test on cobas 6800/8800 Systems

Retrieved on: 
Friday, December 17, 2021
People, DJSI, Hoffmann-La Roche, Omicron, RNA, Genentech, Severe acute respiratory syndrome coronavirus 2, Death, Central nervous system, PCR, Essential medicines, COVID-19 testing, Veni, vidi, vici, Cough, European Centre for Disease Prevention and Control, Public health, Organic acid, World, COVID-19, Severe acute respiratory syndrome coronavirus, Family, Saliva, Risk, JAMA Network Open, Dow Jones, RO, Patient, System, Coinfection, Infection, Collection, Coronavirus, COV, Virus, Control, Genetically modified bacteria, Joint Medical Service (Germany), Ophthalmology, Severe acute respiratory syndrome, CHF, Human, ROG, Pharmaceutical industry, Vaccine, Medical device, Fine chemical, Chugai Pharmaceutical Co.

PLEASANTON, Calif., Dec. 17, 2021 /PRNewswire/ --Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its cobas SARS-CoV-2 Qualitative test has received CE mark for the use of saliva samples in the detection of SARS-CoV-2 on the widely available, high-throughput cobas 6800/8800 Systems.

Key Points: 
  • PLEASANTON, Calif., Dec. 17, 2021 /PRNewswire/ --Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its cobas SARS-CoV-2 Qualitative test has received CE mark for the use of saliva samples in the detection of SARS-CoV-2 on the widely available, high-throughput cobas 6800/8800 Systems.
  • Saliva sample collection represents a convenient testing approach for patients, who can easily self-collect their own samples.
  • "Expanding sensitive testing to include a non-invasive, easy-to-collect sample type such as saliva helps to improve access to screening for more people.
  • The test also provides patients with the option to self-collect their saliva sample on site, following the instructions of a healthcare professional.